2009
DOI: 10.1074/jbc.m808547200
|View full text |Cite
|
Sign up to set email alerts
|

Full Domain Closure of the Ligand-binding Core of the Ionotropic Glutamate Receptor iGluR5 Induced by the High Affinity Agonist Dysiherbaine and the Functional Antagonist 8,9-Dideoxyneodysiherbaine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
92
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 54 publications
(96 citation statements)
references
References 46 publications
(61 reference statements)
3
92
0
Order By: Relevance
“…H͔kainate at recombinant kainate receptors (Lash et al, 2008). o EC 50 for MSVIII-19 at GluK1 recombinant receptors expressed in HEK293 cells treated with Con A. MSVIII-19 failed to displace kainate from recombinant GluK2 expressed in HEK293 cells (Frydenvang et al, 2009). …”
Section: Egebjerg Et Al (1991)mentioning
confidence: 96%
See 1 more Smart Citation
“…H͔kainate at recombinant kainate receptors (Lash et al, 2008). o EC 50 for MSVIII-19 at GluK1 recombinant receptors expressed in HEK293 cells treated with Con A. MSVIII-19 failed to displace kainate from recombinant GluK2 expressed in HEK293 cells (Frydenvang et al, 2009). …”
Section: Egebjerg Et Al (1991)mentioning
confidence: 96%
“…The neodysiherbaine analogs 8-deoxy-neodysiherbaine, 9-deoxy-neodysiherbaine, and MSVIII-19 show nanomolar affinity for GluK1 and Ͼ1000-fold selectivity over GluK2, GluK3, and GluK5, with 8-and 9-deoxy-neodysiherbaine acting as a partial and full agonists, respectively (Lash et al, 2008). MSVIII-19 was originally reported as a GluK1 antagonist (Sanders et al, 2005), but crystallographic studies revealed that it induces full domain closure of the GluK1 LBD, prompting further functional studies that showed it to be an agonist of extremely low efficacy (Frydenvang et al, 2009)…”
Section: Glutamate Receptor Ion Channelsmentioning
confidence: 99%
“…At AMPA-and kainate (KA)-type ionotropic glutamate receptors (iGluRs), initial studies proposed that agonist efficacy resides in the conformations adopted by the agonist-binding domain (ABD) with full agonists more effective at promoting domain closure than partial agonists (Armstrong and Gouaux, 2000;Jin et al, 2003;Mayer, 2005). However, this long-held view has been challenged by more recent work on AMPA receptors (AMPARs) (Zhang et al, 2006(Zhang et al, , 2008 and kainate receptors (KARs) (Fay et al, 2009;Frydenvang et al, 2009) that has failed to report a clear relationship between agonist efficacy and domain closure. From their work on AMPARs, Zhang et al (2006Zhang et al ( , 2008 have proposed that agonist efficacy is determined by the stability of the closedcleft conformation of the ABD.…”
Section: Introductionmentioning
confidence: 91%
“…In this model, full agonists are more effective activators than partial agonists because they promote greater domain closure. However, more recent work on both AMPARs and KARs has questioned the validity of this idea since a clear relationship between agonist efficacy and the extent of domain closure was not able to be established (Zhang et al, 2008;Fay et al, 2009;Frydenvang et al, 2009;Birdsey-Benson et al, 2010). Given this, we reasoned that regions outside the agonistbinding pocket, such as the dimer interface, may have a more prominent role in fine tuning agonist efficacy.…”
Section: Disruption To the Dimer Interface Affects Agonist Responsivementioning
confidence: 99%
“…For example, mutants have been characterized where partial agonists induce complete cleftclosure (Zhang et al, 2008), or where efficacy is related to D2 domain twisting (Birdsey-Benson et al, 2010). For kainate receptor subunits the correlation between cleft-closure and efficacy has also been questioned, with partial agonists again inducing complete cleft-closure in either x-ray structures (Frydenvang et al, 2009) or modeling studies (Fay et al, 2009). In this context, our identification of ligand-specific changes in LBD dimer conformation in the GluK2 Figure 5.…”
Section: Ligand-specific Shifts In Dimer Conformationmentioning
confidence: 99%